- Home
- SEZL vs RARE Comparison
SEZL vs RARE Comparison
Compare SEZL & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEZL
- RARE
- Stock Information
- Founded
- SEZL 2016
- RARE 2010
- Country
- SEZL United States
- RARE United States
- Employees
- SEZL N/A
- RARE N/A
- Industry
- SEZL Diversified Financial Services
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- SEZL Finance
- RARE Health Care
- Exchange
- SEZL Nasdaq
- RARE Nasdaq
- Market Cap
- SEZL 3.0B
- RARE 2.6B
- IPO Year
- SEZL N/A
- RARE 2014
- Fundamental
- Price
- SEZL $89.27
- RARE $30.31
- Analyst Decision
- SEZL Strong Buy
- RARE Strong Buy
- Analyst Count
- SEZL 3
- RARE 14
- Target Price
- SEZL $124.33
- RARE $86.64
- AVG Volume (30 Days)
- SEZL 912.3K
- RARE 1.4M
- Earning Date
- SEZL 11-06-2025
- RARE 11-04-2025
- Dividend Yield
- SEZL N/A
- RARE N/A
- EPS Growth
- SEZL 146.46
- RARE N/A
- EPS
- SEZL 2.93
- RARE N/A
- Revenue
- SEZL $371,794,890.00
- RARE $610,159,000.00
- Revenue This Year
- SEZL $66.31
- RARE $19.72
- Revenue Next Year
- SEZL $28.42
- RARE $23.29
- P/E Ratio
- SEZL $30.44
- RARE N/A
- Revenue Growth
- SEZL 92.95
- RARE 26.77
- 52 Week Low
- SEZL $23.41
- RARE $25.81
- 52 Week High
- SEZL $186.74
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- SEZL 39.83
- RARE 49.05
- Support Level
- SEZL $83.45
- RARE $31.22
- Resistance Level
- SEZL $95.17
- RARE $31.80
- Average True Range (ATR)
- SEZL 4.99
- RARE 0.93
- MACD
- SEZL 1.69
- RARE 0.07
- Stochastic Oscillator
- SEZL 43.98
- RARE 35.88
About SEZL Sezzle Inc.
Sezzle Inc is a financing institution that offers technology-driven payment platform. It allows customers to split their purchase into four installments and pay over 6 weeks with only the first payment due at the time of purchase. Companies operations comprise one reportable segment, the majority of which derives revenue from payment processing platform in North America.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.